Recent Updates in Treatment of Non-Metastatic Castration Resistant Prostate Cancer

Dr Aaron Berger discusses systemic therapy options, treatment selection and monitoring for patients with nonmetastatic castrate-resistant prostate cancer (nmCRPC).

A prostate cancer expert reviews trial design and efficacy data with next-generation androgen receptor inhibitors.

Aaron Berger, MD, discusses adverse events with enzalutamide, apalutamide and darolutamide and their management.

Dr Aaron Berger shares updated safety data on next-generation androgen receptor inhibitors and impact of safety profile on treatment selection in nmCRPC.

A prostate cancer expert discusses comorbidities and dose alterations with next-generation androgen receptor inhibitors in nmCRPC.

Dr Aaron Berger comments on quality of life data and the role of patient preference in nmCRPC.

Aaron Berger, MD, shares unmet needs and challenges in managing patients with nmCRPC.

Aaron Berger, MD, discussed updates in the treatment of nonmetastatic castration-resistant prostate cancer.